Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Chemists Find New Way To Put The Brakes On Cancer

...

10 Sep 2013

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.

6 Sep 2013

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors.

From Cell Signaling Technology 28 Aug 2013

Scientists Shed New Light On Malignant Pancreatic Cancer

...

23 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

OracleBio, providers of high precision digital image analysis services for detailed quantification of histological marker staining within cells and tissues, is pleased to announce it will be a principal sponsor of the forthcoming Tumor Models conference to be held in Boston, MA on the 23-25th July.

24 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

RTI Biologics intents to acquire privately held Pioneer Surgical Technology

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, announced today its intent to acquire privately held Pioneer Surgical Technology, headquartered in Marquette, Mich.

12 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Researchers identify a new mechanism that appears to suppress tumor growth

Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anti-cancer drugs.

4 Jun 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Individual cancer cells that break away from the original tumor and circulate through the blood stream are considered responsible for the development of metastases. These dreaded secondary tumors are the main cause of cancer-related deaths.

23 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

Xenograft News and Research

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

New investigational drug offers potential treatment option for lung cancer

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Chemists Find New Way To Put The Brakes On Cancer

Molecular marker predicts longer survival among patients prescribed two cancer drugs

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Scientists Shed New Light On Malignant Pancreatic Cancer

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

RTI Biologics intents to acquire privately held Pioneer Surgical Technology

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Researchers identify a new mechanism that appears to suppress tumor growth

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News